- Worldwide sales, which neared $300 billion in 2015, were up only 5% over that timeframe, indicating drug companies were squeezing more pro t from every sale.
KEY TAKEAWAY: GSK and Novartis have gone to the outside to hire senior digital marketing people with CPG experience. While these moves are long overdue is it enough or is pharma waiting at the airport for their ship to come in? Continue reading
KEY TAKEAWAY: A study in JAMA found “a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.” Will this be enough to sway insurers to say “ok”? Continue reading
It would be a big mistake to call the legislation Senate Republicans released on Thursday a health care bill. It is, plain and simple, a plan to cut taxes for the wealthy by destroying critical federal programs that help provide health care to tens of millions of people. Even with this charade pharma seems happy because “they got what they want” from this President. Continue reading
KEY TAKEAWAY: The Internet has become a petri dish for bad/fake news. Here are some facts about prescription drugs and health that everyone should be aware of. Continue reading
KEY TAKEAWAY: Net price hikes in the U.S. last year created $8.7 billion in net income for top pharma companies, equivalent to all of the sector’s earnings growth according a new report from Credit Suisse. Profits aren’t enough for pharma companies as The Street wants to see “growth”. Continue reading
KEY TAKEAWAY: The new head of the FDA is promising faster approval of prescription drugs, but without insurer buy-in and in depth clinical trials they could be lighting a giant “warning sign”. Continue reading